Table 1.
The CCND2 methylation level and mRNA expression, and its effects on prognosis in cancers from TCGA.
| Characteristics | Breast Cancer | Lung Cancer | Liver Cancer | Esophageal Cancer | Gastric Cancer | Colon Cancer | |||
|---|---|---|---|---|---|---|---|---|---|
| All 1 | TNBC 2 | All | AD 3 | SCC 4 | |||||
| Hypermethylation on CCND2 gene (paired) | 31/57 (54.4%) | 3/6 (60.0%) | 22/69 (31.9%) | 14/29 (48.3%) | 8/40 (20.0%) | 26/50 (52.0%) | 2/15 (13.3%) | 1/2 (50.0%) | 3/38 (7.9%) |
| Low CCND2 mRNA expressions 5 (paired) | 62/73 *** (84.9%) | 7/7 *** (100%) | 73/90 (81.1%) | 45/49 *** (91.8%) | 28/51 (54.9%) | 21/50 (42.0%) | 7/13 (53.9%) | 22/32 (68.6%) | 13/41 (31.7%) |
| % of methylation and low CCND2 | 43/49 (63.3%) | - | 6/23 (26.1%) | 5/16 (31.3%) | 1/7 (14.3%) | 6/41 (14.6%) | - | - | 2/11 (18.2%) |
| Concordance 6 between methylation & mRNA expression | p = 0.002 ** | - | p = 0.015 * | p = 0.029 * | p > 0.05 | p > 0.05 | - | - | p > 0.05 |
| Prognosis 7 | p = 0.048 * | p = 0.012 * | p = 0.011 * | p > 0.05 | p > 0.05 | p > 0.05 | |||
1 All subtypes of breast cancer. 2 triple-negative breast cancer. 3 Lung adenocarcinoma. 4 Lung squamous cell carcinoma. 5 These results were analyzed by the paired sample T-test. * p < 0.05; ** p < 0.01; *** p < 0. 001. 6 The concordance were analyzed by the Spearman′s rank correlation test. * p < 0.05; ** p < 0.01; *** p < 0. 001. 7 The survival rate were analyzed by the Kaplan Meier method and Log-Rank test. * p < 0.05; ** p < 0.01; *** p < 0. 001.